GLP-1s

Minnesota Live is discussing trending health topics with Dr. Archelle Georgiou, who addresses GLP-1s, peptides, antidepressants, and cancer. The segment aims to provide insights through a trusted medical perspective.

Affordable Care Act insurers are proposing a median 14% premium increase for 2027 due to rising medical costs and policy changes, with enrollment declining by 3 million since February 2023. The expiration of enhanced subsidies under former President Trump and increased demand for costly treatments like GLP-1 weight loss drugs are cited as key factors.

A doctor warns against abruptly discontinuing GLP-1s and outlines a critical plan to maintain weight loss after the jabs.

Medicare is now covering some GLP-1 weight loss drugs for $50, making them more affordable for older Americans. These drugs were previously popular and expensive.

Whey protein, once primarily used by bodybuilders, is now in high demand, leading to supply challenges for US producers. Tony Meives transitioned his family's cheese business to focus on whey protein production. Robert F Kennedy Jr, the US health secretary, declared the 'war on protein' over, signaling a shift in dietary trends.

The Trump administration's deal with Eli Lilly and Novo Nordisk on GLP-1 drugs aimed for lower Medicare/Medicaid prices in exchange for higher sales volume, but companies secured higher sales without lowering prices in some cases. The $245 monthly price was contingent on private insurers covering the drugs with a $50 copay, a condition not publicly disclosed by the administration.

Demand for whey protein is surging in the U.S. due to shifting diet trends and the popularity of GLP-1s, but the dairy industry is unable to meet this growing demand.

The article discusses Micron's strategy to overcome investor concerns related to risk cycles. It also highlights additional topics in the Weekend Reads section, including Medicare, GLP-1s, tech stocks, and career advice.

The article highlights the childhood obesity crisis, noting one in five children in the U.S. have obesity, with seven states exceeding the national average. Doctors are exploring GLP-1s as a potential solution. Additionally, it mentions efforts to raise awareness for rare genetic disorders and a rise in sober social spaces.

Childhood obesity affects one in five children in the U.S., with seven states exceeding the national average. Doctors are exploring GLP-1s as a potential solution. The article also highlights a rare genetic disorder, Mowat-Wilson Syndrome, and a Kansas City initiative promoting alcohol-free social spaces.

Serena Williams, a paid spokesperson for telehealth company Ro, used GLP-1 weight-loss drugs to lose 34 pounds and claims the medication improved her training and tennis performance. The article explores whether GLP-1s should be classified as performance-enhancing drugs, noting the World Anti-Doping Agency is monitoring their use, though current rules allow athletes to take them.

Research suggests weight-loss drugs like Ozempic and Wegovy may help treat or prevent certain cancers. These drugs, part of the GLP-1 class, are now used by one-in-eight American adults.

Overdoses involving GLP-1s are increasing due to their easier availability through telehealth services, which often bypass traditional in-person medical consultations and pharmacies.

Up to 14 million Medicare patients may qualify for GLP-1 drugs at $50 a month for weight loss. These drugs were previously available for diabetes but are now accessible for weight loss under Medicare.

GLP-1 medications improved testosterone levels, sperm count, and sperm morphology in men after 24 weeks, according to a study led by Dr. Pratibha Natesh. However, experts caution more research is needed before prescribing these drugs for male infertility, noting potential risks from sudden weight loss and metabolic changes.

A study by the National Bureau of Economic Research found that middle-aged adults using GLP-1 drugs for obesity could save $192,735 in lifetime medical costs on average, with higher savings ($220,000) for those without college degrees. The study attributes these savings to GLP-1s' direct impact on appetite and metabolism, which benefits individuals with limited time for diet/exercise regimens.

Weight-loss drug users in Great Britain save over £400 annually on grocery bills by purchasing fewer snacks like crisps and chocolate. Use of GLP-1 drugs has nearly tripled in two years, with 1.9 million adults now using them, affecting 6.3% of households.

Recent studies suggest GLP-1s, the weight loss and diabetes drugs, may prevent cancer and slow its progression by acting on brain and metabolic pathways beyond weight loss.

Recent studies suggest GLP-1s, weight loss and diabetes drugs, may prevent cancer and slow its progression. While weight loss is known to reduce cancer risks, GLP-1s might act on additional brain and metabolic pathways to achieve this effect.

People are experiencing 'ghost fat' challenges after losing weight using GLP-1s. The article highlights the phenomenon where visible weight loss does not fully resolve underlying fat issues.

Medicare is promoting GLP-1 drugs Wegovy and Zepbound for weight loss starting July 2024 at $50/month for older adults but has not disclosed the total cost to taxpayers. Massachusetts has filed a lawsuit against United, though details are unspecified in the excerpt.

Telehealth companies offering GLP-1 weight loss medications face scrutiny after patients report severe adverse effects and dosage errors. Karleigh McClain was hospitalized following an overdose linked to a semaglutide prescription from a telehealth provider, highlighting concerns about medication safety and inadequate oversight in online healthcare services.

A weight-loss doctor warns against microdosing GLP-1s for cosmetic weight loss, citing a lack of legitimate long-term data and no standardized definition for the practice. The doctor notes that patients and media are increasingly promoting microdosing despite its unproven efficacy.

Weight-loss drugs like GLP-1s are easily accessible online, leading to concerns about overdoses and safety. The article specifically mentions semaglutide as an example of such drugs used for weight loss and obesity management.

Samsung is collaborating with diabetes experts at Massachusetts General Hospital to test the Galaxy Watch 8's ability to prevent muscle loss in patients using GLP-1 medications like Ozempic. The study aims to leverage wearable technology to address a known side effect of these drugs.

E! host Keltie Knight revealed undergoing a secret facelift at age 41 and admitted feeling shame about the procedure. She also disclosed lying about her weight to obtain GLP-1 weight-loss medications in a candid essay for Glamour magazine.

E! host Keltie Knight revealed undergoing a secret facelift at age 41, expressing feelings of shame, and admitted lying about her weight to obtain GLP-1 weight-loss medications in a Glamour essay.

Research indicates that GLP-1 medications are reducing the need for common bariatric procedures like gastric sleeve surgery and gastric bypass. These surgeries are among the most frequently performed weight-loss interventions.

The peptide market is expanding rapidly, driven by popularity among wellness influencers and claims of benefits like muscle growth and anti-aging. However, many peptides lack FDA safety and efficacy oversight, raising concerns as the FDA considers easing restrictions. Experts warn of risks from unregulated products and emphasize the need for clinical rationale and professional guidance.

Teddi Mellencamp, a public figure, has expressed her desire to use GLP-1 medications to lose weight while undergoing treatment for stage 4 cancer. Her statement highlights the intersection of weight management and serious health challenges.